Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/200303METHODS FOR THE DIAGNOSIS AND TREATMENT OF T CELL-LYMPHOMAS
WO 29.09.2022
Int.Class A61P 35/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Appl.No PCT/EP2022/057408 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor BENSUSSAN, Armand
T-cell lymphomas are a heterogeneous group of malignancies involving T lymphocytes and generally characterized by a poor prognosis. Among them, cutaneous T-cell lymphomas involve primarily the skin. Mycosis fungoides and Sezary syndrome are the most frequent cutaneous T-cell lymphomas. The inventors studied the regulatory T phenotype of Sezary cells and showed the expression of CCR8 (CD198) by Sezary cells and other T-cell lymphoma cell lines. CCR8 therefore appears as a useful diagnostic, prognostic and follow-up marker, and as a potential therapeutic target in T-cell lymphomas. Therapeutic depletion of CCR8-expressing cancer cells would eliminate tumor cells and also activate the anti-tumor immunity in T-cell lymphomas.
2.WO/2022/204173METHODS FOR PREDICTING TREATMENT OUTCOME TO CHECKPOINT INHIBITORS IN CANCER
WO 29.09.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/US2022/021377 Applicant THE BRIGHAM AND WOMEN'S HOSPITAL, INC. Inventor MINEO, Marco
Described herein are methods of selecting a treatment for, and optionally treating, a subject who has a tumor and methods for determining is a subject who has a tumor is likely to benefit from an immunotherapy treatment. The methods disclosed herein can include the use of a long non-coding RNA, and/or a ribonucleoprotein, as biomarkers of patient response to immunotherapy treatment, such as an immune checkpoint inhibitor.
3.WO/2022/202853EFFICACIOUS ANTI-CD26 ANTIBODY BIOMARKER
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/JP2022/013309 Applicant Y'S AC CO., LTD. Inventor MORIMOTO, Chikao
In the present invention, a potential prognostic biomarker for CD26-targeted therapy was identified based on phase I trial data of the humanized anti-CD26 monoclonal antibody YS110 for CD26-expressing tumors. Box-and-whisper plot analysis, scatter plot analysis, Pearson's product-moment correlation/Spearman's rank-order correlation, bar graph analysis and receiver operating characteristics (ROC) were used to examine the correlation between soluble CD26 titer variation with YS110 administration and tumor volume change, RECIST criteria evaluation and progression free survival (PFS). The mechanism for serum soluble CD26 titer variation was confirmed by in vitro experimentation. As a result, it was discovered, for the first time, that serum soluble CR26/DPP4 titer variation in the early stage of YS110 treatment is a predictive biomarker for evaluating thereapeutic effect.
4.WO/2022/204293SELECTIVE TARGETING OF OLIGOMERIC Β‑AMYLOID
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2022/021567 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor HE, Ping
The invention provides methods and compositions for treating or ameliorating Alzheimer's disease. The invention provides agents that reduce Aβ inclusions and plaque accumulation, inhibit dendrite spine loss, and restore neurogenesis.
5.WO/2022/201084METHODS FOR TREATING OCULAR DISEASES
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/IB2022/052692 Applicant NOVARTIS AG Inventor EHLERS, Justis P.
The invention relates to methods for treating ocular disease with a VEGF antagonist. In particular, the invention relates to methods for treating ocular disease, the method comprising selectively administering a VEGF antagonist to a subject in need thereof on the basis of said subject not having a preretinal or vitreous hyperreflective foci formation. The invention further relates to methods for determining whether a subject with ocular disease should be treated with a VEGF antagonist, methods of predicting the likelihood that a subject having ocular disease will develop intraocular inflammation in response to a treatment with a VEGF antagonist, and methods for producing a transmittable form of information for determining whether a subject with ocular disease should be treated with a VEGF antagonist or for predicting whether a subject with ocular disease may develop intraocular inflammation in response to a treatment with a VEGF antagonist.
6.WO/2022/202854MIRNAS, COMPOSITIONS, AND METHODS OF USING THEREOF
WO 29.09.2022
Int.Class C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
Appl.No PCT/JP2022/013311 Applicant CRAIF INC. Inventor YAMAGUCHI Hiroki
A method for identifying a patient as having a marker correlated with systemic lupus erythematosus (SLE) comprises obtaining a body fluid sample from a patient suspected of having SLE, analyzing miRNA expression in the obtained body fluid sample, and identifying the patient as having the marker correlated with SLE if an increase in expression of at least one miRNA selected from SEQ ID NOs: 1-160 and 243-402 and/or a decrease in expression of at least one miRNA selected from SEQ ID NOs: 161-242 and 403-484 compared to a body fluid sample obtained from a healthy individual is detected in the patient sample, or as not having the marker correlated with SLE if an increase in expression of at least one miRNA selected from SEQ ID NOs: 1-160 and 243-402 and/or a decrease in expression of at least one miRNA selected from SEQ ID NOs: 161-242 and 403-484 compared to a body fluid sample obtained from a healthy individual fails to be detected.
7.WO/2022/200478TUMOR TREATMENT WITH A 4-1BB/HER2-BISPECIFIC AGENT AND A HER2-TARGETED TYROSINE KINASE INHIBITOR
WO 29.09.2022
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/EP2022/057721 Applicant PIERIS PHARMACEUTICALS GMBH Inventor JAQUIN, Thomas
The disclosure provides methods and compositions for treating tumors, particularly HER2- expressing tumors, including tumors characterized by a low expression of HER2 and HER2- positive (HER2+) tumors. The method comprises administering a HER2/4-1BB-bispecific agent and a HER2-targeted tyrosine kinase inhibitor (TKI). The disclosure further provides combinations and kits of parts comprising a HER2/4-1 BB-bispecific agent and a HER2-targeted TKI.
8.WO/2022/201123ANTI-TAU ANTIBODIES AND USES THEREOF
WO 29.09.2022
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/IB2022/052765 Applicant JANSSEN BIOTECH, INC. Inventor NANJUNDA, Rupesh
Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies for treating or preventing conditions such as tauopathies.
9.WO/2022/202953ANTIBODY OR FRAGMENT THEREOF, AND METHOD FOR USING SAME
WO 29.09.2022
Int.Class C07K 16/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
30from tumour cells
Appl.No PCT/JP2022/013783 Applicant NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM Inventor TAKEUCHI, Tamotsu
The present invention provides antibody, or a fragment thereof, that recognizes an antigen specific to colon cancer or oral cancer. Specifically, the present invention provides antibody, or a fragment thereof, that recognizes the N-linked sugar chain of annexin A2.
10.WO/2022/203043SUPPRESSANT FOR NERVOUS SYSTEM VASCULAR BARRIER BREAKDOWN, AND THERAPEUTIC AGENT FOR NERVOUS SYSTEM DISORDERS
WO 29.09.2022
Int.Class A61K 38/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
43Enzymes; Proenzymes; Derivatives thereof
46Hydrolases (3)
47acting on glycosyl compounds (3.2), e.g. cellulases, lactases
Appl.No PCT/JP2022/014394 Applicant YAMAGUCHI UNIVERSITY Inventor IKEDA Eiji
The present invention addresses the problem of providing a suppressant for nervous system vascular barrier breakdown. Provided is a suppressant for nervous system vascular barrier breakdown, the suppressant comprising (a) or (b) as an active ingredient: (a) an enzyme capable of specifically detaching or decomposing a sugar chain of low-glycosylated basigin; and (b) an antibody, an aptamer, or a lectin that specifically binds to low-glycosylated basigin and suppresses the nervous system vascular barrier breakdown caused by basigin. Preferably, the sugar chain of the low-glycosylated basigin is high-mannose sugar chain.